Zalicus to discontinue Z160 program after Phase 2 miss

• Zalicus (ZLCS) announces top-line results from two Phase 2 studies of Z160 in lumbosacral radiculopathy and post-herpetic neuralgia.
• Z160 did not meet its primary endpoint in either study.
• ZLCS will now discontinue the Z160 program and focus on Z944.
• "Despite its promising preclinical profile, Z160 was unable to translate those results into clinical efficacy," CEO Mark Corrigan says. (PR)
  
• Shares are halted and will resume trading at 9:00 am ET.